Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2024 Jun;103(7):1111-1124.
doi: 10.1002/ccd.31039. Epub 2024 Apr 9.

One-year initial efficacy and safety outcomes of the premounted dry-pericardium Vienna self-expandable transcatheter aortic valve system: A first-in-human VIVA feasibility study

Kasparas Briedis  1 , Egle Rumbinaite  1   2 , Ali Aldujeli  1 , Kamilija Briede  1 , Martynas Jurenas  1 , Povilas Jakuska  2 , Antanas Jankauskas  3 , Indre Ceponiene  1 , Tadas Lenkutis  2 , Jurgita Plisiene  1 , Rimantas Benetis  2 , Remigijus Zaliunas  1
Affiliations
Clinical Trial

One-year initial efficacy and safety outcomes of the premounted dry-pericardium Vienna self-expandable transcatheter aortic valve system: A first-in-human VIVA feasibility study

Kasparas Briedis et al. Catheter Cardiovasc Interv. 2024 Jun.

Abstract

Background: The dry-pericardium Vienna transcatheter aortic valve system is repositionable and retrievable, already premounted on the delivery system, eliminating the need for assembly and crimping of the device before valve implantation.

Methods: The VIVA first-in-human feasibility study, a prospective, nonrandomized, single-center trial, evaluated the Vienna aortic valve in 10 patients with severe symptomatic aortic stenosis, who were at intermediate or high surgical risk. This study, registered at ClinicalTrials.gov (NCT04861805), focused on the safety, feasibility, clinical and hemodynamic performance of the Vienna system up to 1-year follow-up.

Results: The mean patient age was 79 ± 5 years, 60% male. Valve sizes used: 26 mm (10%), 29 mm (30%), 31 mm (60%). Key hemodynamic improvements were significant: mean aortic valve pressure gradient (mmHg) decreased from 48.7 to 8.1, aortic valve area (cm2) increased from 0.75 to 1.91, and maximum jet velocity through the aortic valve (m/s) decreased from 4.41 to 1.95 (p < 0.0001). No moderate/severe paravalvular leakage was observed, and computed tomography scans revealed no evidence of hypo-attenuated leaflet thickening. The study recorded one life-threatening bleeding event, two cases requiring postprocedural pacemaker implantation, and three ischemic events, with only one causing lasting neurological impairment. Importantly, there were no cases of cardiovascular mortality and only one noncardiovascular death, which was confirmed as unrelated to the device.

Conclusions: The study indicates the Vienna valve as a potential option for severe symptomatic aortic stenosis, designed to streamline the procedure and potentially lower healthcare costs by reducing resource and equipment needs, also procedural errors. Further research is essential to thoroughly evaluate its safety and efficacy.

Keywords: TAVI; VIVA trial; Vienna TAVI; first‐in‐human.

PubMed Disclaimer

References

REFERENCES

    1. McKavanagh P, Zawadowski G, Ahmed N, Kutryk M. The evolution of coronary stents. Expert Rev Cardiovasc Ther. 2018;16(3):219‐228.
    1. Briedis K, Aldujeli A, Zaliunas R, Benetis R. Early safety and performance of the premounted dry‐pericardium Vienna self‐expandable transcatheter aortic valve system: 30‐day outcomes of the first‐in‐human VIVA feasibility study. Am J Cardiol. 2023;204:302‐311.
    1. Briedis K, Mizariene V, Rumbinaite E, et al. Safety and performance of the Vienna self‐expandable transcatheter aortic valve system: 6‐month results of the VIVA first‐in‐human feasibility study. Front Cardiovasc Med. 2023;10:10.
    1. Kappetein AP, Head SJ, Généreux P, et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the valve academic research consortium‐2 consensus document. Eur Heart J. 2012;33(19):2403‐2418.
    1. Généreux P, Head SJ, Van Mieghem NM, et al. Clinical outcomes after transcatheter aortic valve replacement using valve academic research consortium definitions. J Am Coll Cardiol. 2012;59(25):2317‐2326. https://www.sciencedirect.com/science/article/pii/S0735109712009278

Publication types

MeSH terms

Associated data

LinkOut - more resources